Sonpavde GP - Search Results

1

Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.

Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, Tagawa ST, Molina AM, Sternberg CN, Nanus DM, Mosquera JM, Elemento O, Sonpavde GP, Grivas P, Vogelzang NJ, Faltas BM. Shohdy KS, et al. Among authors: sonpavde gp. Br J Cancer. 2022 Feb;126(3):430-439. doi: 10.1038/s41416-021-01648-8. Epub 2022 Jan 19. Br J Cancer. 2022. PMID: 35046520 Free PMC article.

2

Novel agents for muscle-invasive and advanced urothelial cancer.

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Sonpavde G, et al. BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005203 Review.

3

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.

Sonpavde G, Hutson TE, Sternberg CN. Sonpavde G, et al. Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253. Expert Opin Investig Drugs. 2008. PMID: 18230058 Review.

4

Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.

Sonpavde G, Sternberg CN. Sonpavde G, et al. BJU Int. 2008 Nov;102(9 Pt B):1354-60. doi: 10.1111/j.1464-410X.2008.07982.x. BJU Int. 2008. PMID: 19035904 Review.

5

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.

Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, Trump DL, Natale RB, Grossman HB, Crawford ED. Sonpavde G, et al. Cancer. 2009 Sep 15;115(18):4104-9. doi: 10.1002/cncr.24466. Cancer. 2009. PMID: 19517476 Free PMC article.

6

Satraplatin for the therapy of castration-resistant prostate cancer.

Sonpavde G, Sternberg CN. Sonpavde G, et al. Future Oncol. 2009 Sep;5(7):931-40. doi: 10.2217/fon.09.84. Future Oncol. 2009. PMID: 19792961 Review.

7

Pazopanib for the treatment of renal cell carcinoma and other malignancies.

Sonpavde G, Hutson TE, Sternberg CN. Sonpavde G, et al. Drugs Today (Barc). 2009 Sep;45(9):651-61. Drugs Today (Barc). 2009. PMID: 19956806 Review.

8

The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.

Sonpavde G, Sternberg CN. Sonpavde G, et al. Int J Urol. 2010 Mar;17(3):228-40. doi: 10.1111/j.1442-2042.2010.02449.x. Epub 2010 Jan 19. Int J Urol. 2010. PMID: 20088874 Review.

9

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.

Sonpavde G, Rosenberg JE, Hahn NM, Galsky MD, Bangs R, Sternberg CN, Vogelzang NJ. Sonpavde G, et al. J Clin Oncol. 2010 May 1;28(13):e205-7; author reply e208. doi: 10.1200/JCO.2009.27.1114. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159797 No abstract available.

10

Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.

Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G. Agarwal N, et al. Future Oncol. 2010 May;6(5):665-79. doi: 10.2217/fon.10.48. Future Oncol. 2010. PMID: 20465382 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

491 results

Search Page

Filters